

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA137; Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)**

This guidance was issued February 2008 with a review date of December 2010

**Background**

At the GE meeting of 7 December 2010 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

|  |  |
|--|--|
| <b>Proposal put to consultees:</b>           | A review of the guidance should be transferred to the "static guidance list".                                    |
| <b>Rationale for selecting this proposal</b> | There is no new compelling evidence to suggest a review should be undertaken and no new evidence is anticipated. |

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

|  |   |
|--|---|
| <b>Recommendation post consultation:</b> | The guidance should be transferred to the "static guidance list". |
|--|---|

| <b>Respondent</b>                              | <b>Response to proposal</b> | <b>Details</b>   | <b>Comment from Technology Appraisals</b> |
|--|-----------------------------|--|---|
| Leukaemia CARE                                 | Agree                       | I am in full agreement, as there is no new evidence available to justify a review, this HTA should be moved to the static list.  | Comment noted                             |
| Royal College of Nursing of the United Kingdom | Agree                       | Nurses caring for lymphoma patients have considered the proposals regarding the review of the above technology appraisal guidance. They are not aware of any new relevant evidence that would have a material effect on the guidance. There are no further comments to make on behalf of the Royal College of Nursing on the proposal to move the guidance to the static list. | Comment noted                             |
| Public Health Wales NHS Trust                  | Agree                       | The Public Health Wales NHS Trust agrees with the proposal to move the guidance to the static list.  | Comment noted                             |

| <b>Respondent</b>   | <b>Response to proposal</b> | <b>Details</b>  | <b>Comment from Technology Appraisals</b> |
|---|-----------------------------|---|---|
| National Cancer Research Institute/Royal College of Physicians/<br>Royal College of Radiologists/<br>Association of Cancer Physicians/Joint Collegiate Council for Oncology | Agree                       | The NCRI/RCR/RCR/ACP/JCCO have no objection to the proposal to move this guidance to the static list. | Comment noted                             |

**No response received from:**

|   |   |
|---|---|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"><li>• Roche Products (rituximab)</li></ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"><li>• Afiya Trust</li><li>• African Caribbean Leukaemia Trust</li><li>• Anthony Nolan Bone Marrow Trust</li><li>• Black Health Agency</li><li>• Cancer Black Care</li><li>• Cancer Equality</li><li>• CANCERactive</li><li>• Chinese National Healthy Living Centre</li><li>• Counsel and Care</li><li>• Equalities National Council</li><li>• Helen Rollason Heal Cancer Charity</li><li>• Leukaemia Society (UK)</li><li>• Lymphoma Association</li><li>• Macmillan Cancer Support</li><li>• Maggie's Centres</li><li>• Marie Curie Cancer Care</li><li>• Muslim Council of Britain</li><li>• Muslim Health Network</li><li>• South Asian Health Foundation</li><li>• Specialised Healthcare Alliance</li><li>• Sue Ryder Care</li><li>• Tenovus</li></ul> | <p><u>General</u></p> <ul style="list-style-type: none"><li>• Board of Community Health Councils in Wales</li><li>• British National Formulary</li><li>• Care Quality Commission</li><li>• Commissioning Support Appraisals Service</li><li>• Department of Health, Social Services and Public Safety for Northern Ireland</li><li>• Medicines and Healthcare products Regulatory Agency</li><li>• National Association of Primary Care</li><li>• NHS Alliance</li><li>• NHS Commercial Medicines Unit</li><li>• NHS Confederation</li><li>• NHS Quality Improvement Scotland</li><li>• Scottish Medicines Consortium</li></ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"><li>• Actavis (fludarabine)</li><li>• Aspen Medical Europe (chlorambucil)</li><li>• Baxter Healthcare (cyclophosphamide, mitoxantrone)</li><li>• Eli Lilly (vincristine)</li><li>• Genzyme Therapeutics (fludarabine)</li><li>• GlaxoSmithKline (chlorambucil, tositumomab)</li><li>• Hameln Pharmaceuticals (hydroxydaunomycin)</li><li>• Hospira (fludarabine, hydroxydaunomycin, mitoxantrone, vincristine)</li><li>• Medac uk (hydroxydaunomycin)</li><li>• Merck Sharp &amp; Dohme UK (hydroxydaunomycin)</li></ul> |
|---|---|

### Professional groups

- British Association for Services to the Elderly
- British Geriatrics Society
- British Oncological Association
- British Psychosocial Oncology Society
- British Society for Haematology
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society of Great Britain
- Royal Society of Medicine Intellectual Disability Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

### Others

- Department of Health
- NHS Coventry
- NHS Hammersmith and Fulham
- Welsh Assembly Government

- Pfizer (cyclophosphamide, hydroxydaunomycin and mitoxantrone)
- Teva UK (fludarabine, hydroxydaunomycin, mitoxantrone, vincristine)
- Wockhardt (fludarabine, hydroxydaunomycin, mitoxantrone)

### Relevant research groups

- British National Lymphoma Investigation
- Elimination of Leukaemia Fund
- Institute of Cancer Research
- Leukaemia & Lymphoma Research
- MRC Clinical Trials Unit
- National Cancer Research Network
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute of the Care of Older People

### Assessment Group

- National Institute for Health Research Health Technology Assessment Programme
- Tbc

### Associated Guideline Groups

- National Collaborating Centre for Cancer

|  |  |
|--|--|
|  | <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"><li>• None</li></ul> |
|--|--|

**GE paper sign-off:** Janet Robertson, Associate Director – Technology Appraisals Programme

**Contributors to this paper:**

Technical Lead: Helen Tucker

Technical Adviser: Rebecca Trowman

Project Manager: Kate Moore

16 February 2011